CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
folate receptor alpha-expressing (5% or higher) platinum resistant ovarian cancerThe dose escalation part of the study will primari...
Phase 1
London, United Kingdom and 6 other locations
of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...
Phase 3
London, United Kingdom and 125 other locations
The goal of this clinical trial is to establish if THEO-260 is safe to administer to adult females with ovarian cancer. It will als ...
Phase 1, Phase 2
London, United Kingdom
mirvetuximab soravtansine (MIRV) in patients with platinum resistant ovarian cancer. Approximately 102 patients will be enrolled in...
Phase 1
London, London, city of, United Kingdom and 20 other locations
the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...
Phase 2
London, United Kingdom and 46 other locations
positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 pri...
Phase 2
London, United Kingdom and 70 other locations
of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...
Phase 3
London, United Kingdom and 92 other locations
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....
Phase 3
London, United Kingdom and 176 other locations
phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be...
Phase 1
London Borough of Sutton, Sutton Surrey, United Kingdom and 21 other locations
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (I...
Phase 3
London, United Kingdom and 50 other locations
Clinical trials
Research sites
Resources
Legal